Nikesha Gilmore

Nikesha Gilmore

Auto-generated profile, based on publicly available information

Nikesha Gilmore

University of Rochester Medical Center Rochester New York

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
NGNikesha Gilmore
Nikesha Gilmore
LKLee Kehoe
Lee Kehoe
JBJessica Bauer
Jessica Bauer
HXHuiwen Xu
Huiwen Xu
BHBianca Hall
Bianca Hall
SMSupriya Mohile
Supriya Mohile
Background: Aging-related deficits that eventually manifest as frailty may be associated with poor emotional health in older patients with advanced cancer. This study aimed to examine the relationship between frailty and emotional health in this population.Methods: This was a secondary analysis of baseline data from a nationwide cluster randomized trial. Patients were aged ≥70 years with incurable stage III/IV solid tumors or lymphomas, had ≥1 geriatric assessment (GA) domain impairment, and had completed the Geriatric Depression Scale, Generalized Anxiety Disorder-7, and Distress Thermometer. Frailty was assessed using a Deficit Accumulation Index (DAI; range 0–1) based on GA, which did not include emotional health variables (depression and anxiety), and participants were stratified into robust, prefrail, and frail categories. Multivariate logistic regression models examined the association of frailty with emotional health outcomes. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were reported.Results: Five hundred forty-one patients were included (mean age: 77 years; 70–96). DAI ranged from 0.04 to 0.94; 27% of patients were classified as robust, 42% prefrail, and 31% frail. Compared with robust patients, frail patients had an increased risk of screening positive for depression (aOR = 12.8; 95% CI = 6.1–27.0), anxiety (aOR = 6.6; 95% CI = 2.2–19.7), and emotional distress (aOR = 4.62; 95% CI = 2.9–8.3). Prefrail compared with robust patients also had an increased risk of screening positive for depression (aOR = 2.22; 95% CI = 1.0–4.8) and distress (aOR = 1.71; 95% CI = 1.0–2.8).Conclusion: In older patients with advanced cancer, frailty is associated with poorer emotional health, which indicates a need for an integrated care approach to treating these patients.Implications for Practice: A relationship exists between frailty and poor emotional health in older adults with advanced cancer. Identifying areas of frailty can prompt screening for emotional health and guide delivery of appropriate interventions. Alternatively, attention to emotional health may also improve frailty.

1 October 2021 in Cancer Epidemiology
Verified
Journal Article
Closed access
AGAbdi T. Gudina
Abdi T. Gudina
VCVinay K. Cheruvu
Vinay K. Cheruvu
NGNikesha J. Gilmore
Nikesha J. Gilmore
AKAmber S. Kleckner
Amber S. Kleckner
EAEvelyn Arana-Chicas
Evelyn Arana-Chicas
ACAna Paula Cupertino
Ana Paula Cupertino

12 April 2021 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
HXHuiwen Xu
Huiwen Xu
SKSindhuja Kadambi
Sindhuja Kadambi
SMSupriya G. Mohile
Supriya G. Mohile
SYShuhan Yang
Shuhan Yang
LKLee A. Kehoe
Lee A. Kehoe
KLKah Poh Loh
Kah Poh Loh

19 August 2020 in Nutrition and Cancer
Verified
Journal Article
Open access
JIJulia E. Inglis
Julia E. Inglis
AKAmber S. Kleckner
Amber S. Kleckner
PLPo-Ju Lin
Po-Ju Lin
NGNikesha J. Gilmore
Nikesha J. Gilmore
ECEva Culakova
Eva Culakova
LPLuke Joseph Peppone
Luke Joseph Peppone
Cancer-related fatigue (CRF) is a common side effect impacting breast cancer survivors. Research points to a relationship between obesity and CRF in breast cancer survivors related to elevated syst...

5 February 2021 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
NGNikesha Gilmore
Nikesha Gilmore
SMSupriya Mohile
Supriya Mohile
LLLianlian Lei
Lianlian Lei
ECEva Culakova
Eva Culakova
MMMostafa Mohamed
Mostafa Mohamed
MJMichelle Janelsins
Michelle Janelsins
Background: Frailty is associated with an increased risk of chemotherapy toxicity. Cellular markers of inflammation can help identify patients with frailty characteristics. However, the role of cellular markers of inflammation in identifying patients at risk of developing chemotherapy-induced frailty and their clinical utility are not fully understood. Methods: This study was a secondary analysis of a large nationwide cohort study of women with stage I–IIIC breast cancer (n = 581, mean age 53.4; range 22–81). Measures were completed pre-chemotherapy (T1), post-chemotherapy (T2), and 6 months post-chemotherapy (T3). Frailty was assessed at all three time points using a modified Fried score consisting of four self-reported measures (weakness, exhaustion, physical activity, and walking speed; 0–4, 1 point for each). Immune cell counts as well as neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR) were obtained at T1 and T2 time points. Separate linear regressions were used to evaluate the associations of (1) cell counts at T1 with frailty at T1, T2, and T3 and (2) change in cell counts (T2–T1) with frailty at T2 and T3. We controlled for relevant covariates and frailty at the T1 time point. Results: From T1 to T2, the mean frailty score increased (1.3 vs 2.0; p < 0.01) and returned to T1 levels by the T3 time point (1.3 vs 1.3; p = 0.85). At the T1 time point, there was a positive association between cellular markers of inflammation and frailty: WBC (β = 0.04; p < 0.05), neutrophils (β = 0.04; p < 0.05), and NLR (β = 0.04; p < 0.01). From T1 to T2, a greater increase in cellular markers of inflammation was associated with frailty at T2 (WBC: β = 0.02, p < 0.05; neutrophils: β = 0.03, p < 0.05; NLR: β = 0.03; p < 0.01). These associations remained significant after controlling for the receipt of growth factors with chemotherapy and the time between when laboratory data was provided and the start or end of chemotherapy. Conclusions: In patients with breast cancer undergoing chemotherapy, cellular markers of inflammation are associated with frailty. Immune cell counts may help clinicians identify patients at risk of frailty during chemotherapy. Trial registration: ClinicalTrials.gov, NCT01382082

4 February 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
EBElizabeth K Belcher
Elizabeth K Belcher
ECEva Culakova
Eva Culakova
NGNikesha J Gilmore
Nikesha J Gilmore
SHSara J Hardy
Sara J Hardy
AKAmber S. Kleckner
Amber S. Kleckner
MJMichelle Janelsins
Michelle Janelsins
Inflammation may contribute to cognitive difficulties in patients with breast cancer. We tested 2 hypotheses: inflammation is elevated in patients with breast cancer vs noncancer control participants and inflammation in patients is associated with worse attention and processing speed over the course of chemotherapy. Serum cytokines (interleukin [IL]–4, 6, 8, 10; tumor necrosis factor [TNF]–α) and soluble receptors [sTNFRI, II]) were measured in 519 females with breast cancer before and after chemotherapy and 338 females without cancer serving as control participants. Attention and processing speed were measured by Rapid Visual Processing (RVP), Backward Counting (BCT), and Trail Making-A (TMT-A) tests. Linear regression models examined patient vs control cytokines and receptor levels, adjusting for covariates. Linear regression models also examined relationships between patient cytokines and receptor levels and test performance, adjusting for age, body mass index, anxiety, depression, cognitive reserve, and chemotherapy duration. Statistical tests were 2-sided (α = .05). sTNFRI and sTNFRII increased over time in patients relative to controls, whereas IL-4, IL-6, and IL-10 decreased. Prechemotherapy, higher IL-8 associated with worse BCT (β = 0.610, SE = 0.241, P = .01); higher IL-4 (β = −1.098, SE = 0.516, P = .03) and IL-10 (β = −0.835, SE = 0.414, P = .04) associated with better TMT-A. Postchemotherapy, higher IL-8 (β = 0.841, SE = 0.260, P = .001), sTNFRI (β = 6.638, SE = 2.208, P = .003), and sTNFRII (β = 0.913, SE = 0.455, P = .045) associated with worse BCT; higher sTNFRII also associated with worse RVP (β = −1.316, SE = 0.587, P = .03). At prechemotherapy, higher IL-4 predicted RVP improvement over time (β = 0.820, SE = 0.336, P = .02); higher sTNFRI predicted worse BCT over time (β = 5.566, SE = 2.367, P = .02). Longitudinally, increases in IL-4 associated with BCT improvement (β = −0.564, SE = 0.253, P = .03). Generally, worse attention and processing speed were associated with higher inflammatory cytokines and receptors and lower anti-inflammatory cytokines in patients; future confirmatory studies are needed.